<PAGE>
As filed with the Securities and Exchange Commission on February 6, 1997
Registration No. 333-
================================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
--------------------
FORM S-3
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
--------------------
RENAL TREATMENT CENTERS, INC.
------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 23-2518331
------------------------- -------------------
(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)
Building 2, Suite 300
1180 West Swedesford Road
Berwyn, Pennsylvania 19312
(610) 644-4796
---------------------------------------------------
(Address, including zip code, and telephone number, including
area code, of registrant's principal executive offices)
--------------------
Thomas J. Karl, Esquire
Vice President, Secretary and General Counsel
Building 2, Suite 300
1180 West Swedesford Road
Berwyn, Pennsylvania 19312
(610) 644-4796
---------------------------------------------------
(Name, address, including zip code, and telephone number,
including area code, of agent for service)
--------------------
Copy to:
Kathleen M. Shay, Esquire
Duane, Morris & Heckscher
One Liberty Place
Philadelphia, PA 19103-7396
--------------------
Approximate date of commencement of proposed sale to the public: From time to
time after the effective date of this Registration Statement.
If the only securities being registered on this form are being offered
pursuant to dividend or interest reinvestment plans, please check the following
box. [ ]
If any of the securities being registered on this form are to be offered on a
delayed or continuous basis pursuant to Rule 415 under the Securities Act of
1933, other than securities offered only in connection with dividend or interest
reinvestment plans, check the following box. [X]
<PAGE>
If this form is filed to register additional securities for an offering
pursuant to Rule 462(b) under the Securities Act of 1933, please check the
following box and list the Securities Act registration number of the earlier
effective registration statement for the same offering. [ ]
--------------
If this form is a post-effective amendment filed pursuant to Rule 462(c) under
the Securities Act of 1933, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement
for the same offering. [ ]
--------------
If delivery of the prospectus is expected to be made pursuant to Rule 434
under the Securities Act of 1933, please check the following box. [ ]
-------------------
<TABLE>
<CAPTION>
CALCULATION OF REGISTRATION FEE
====================================================================================
Proposed Proposed
Title of securities Amount to maximum maximum Amount of
to be registered be offering aggregate registration fee
registered price offering price
per
share
- -------------------------------------------------------------------------------------
<S> <C> <C> <C> <C>
Common Stock, 30,000 $28.00 $840,000.00(1) $255.00
$.01 par value shares
=====================================================================================
</TABLE>
(1) Pursuant to paragraph (c) of Rule 457, the proposed maximum offering price
per share and the proposed maximum aggregate offering price have been
computed on the basis of $28.00 per share, the average of the high and low
sales prices of the Common Stock of the Company on the New York Stock
Exchange on February 4, 1997.
-----------------
The registrant hereby amends this Registration Statement on such date or
dates as may be necessary to delay its effective date until the registrant
shall file a further amendment which specifically states that this
Registration Statement shall thereafter become effective in accordance with
Section 8(a) of the Securities Act of 1933, or until the Registration
Statement shall become effective on such date as the Commission, acting
pursuant to said Section 8(a), may determine.
<PAGE>
SUBJECT TO COMPLETION, DATED FEBRUARY 6, 1997
PROSPECTUS
30,000 Shares
RENAL TREATMENT CENTERS, INC.
Common Stock
($.01 par value)
-----------------------------------
This Prospectus relates to 30,000 shares (the "Shares") of Common
Stock, $.01 par value, of Renal Treatment Centers, Inc. (the "Company") that may
be acquired by certain securityholders of the Company (the "Selling
Stockholders") in private transactions upon exercise of options to purchase the
Shares. See "Selling Stockholders." Some or all of the shares of Common Stock to
which this Prospectus relates may be sold from time to time by the Selling
Stockholders, or by pledges, donees, transferees or other successors in interest
to the Selling Stockholders, at public or private sale at prevailing market
prices, prices related to prevailing market prices, negotiated prices or fixed
prices (and, in the case of sales through brokers, upon payment of normal
brokerage commissions). The Company will not receive any of the proceeds from
the sale of the shares of Common Stock offered hereunder by the Selling
Stockholders.
The Common Stock of the Company is quoted on the New York Stock
Exchange under the symbol "RXT." The last reported sale price of the Common
Stock on the New York Stock Exchange on February 4, 1997 was $28.25 per share.
---------------------
THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE
SECURITIES AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION
NOR HAS THE SECURITIES AND EXCHANGE COMMISSION OR ANY STATE SECURITIES
COMMISSION PASSED UPON THE ACCURACY OR ADEQUACY OF THIS PROSPECTUS.
ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.
See "Risk Factors" beginning on page 2 for a discussion of certain
factors that should be considered by prospective purchasers of the securities
offered hereby.
This Prospectus does not constitute an offer to sell securities in any
jurisdiction to any person to whom it is unlawful to make such offer in such
jurisdiction.
No person has been authorized by the Company to give any information
or to make any representations, other than as contained in this Prospectus, and,
if given or made, such information or representations must not be relied upon.
Neither delivery of this Prospectus nor any sale made hereunder shall, under any
circumstances, create any implication that there has been no change in the
affairs of the Company since the date hereof.
Unless the context otherwise requires, the term "Company" refers to
Renal Treatment Centers, Inc. and its subsidiaries.
The date of this Prospectus is , 1997
<PAGE>
AVAILABLE INFORMATION
The Company is subject to the reporting requirements of the Securities
Exchange Act of 1934, as amended (the "Exchange Act"), and in accordance
therewith files reports, proxy statements and other information with the
Securities and Exchange Commission (the "Commission"). Such reports, proxy
statements and other information can be inspected and copied at the offices of
the Commission at Room 1024, Judiciary Plaza, 450 Fifth Street, N.W.,
Washington, D.C. 20549, as well as at the following regional offices of the
Commission: Seven World Trade Center, Suite 1300, New York, New York 10048; and
500 West Madison Street, Suite 1400, Chicago, Illinois 60661. Copies of such
materials can be obtained from the Public Reference Section of the Commission at
450 Fifth Street, N.W., Washington, D.C. 20549 at prescribed rates. In addition,
the Commission maintains a Web site that contains such materials at
http://www.sec.gov. The Company's Common Stock is listed on the New York Stock
Exchange, 20 Broad Street, New York, New York 10005, and such reports, proxy
statements and other information concerning the Company can be inspected at such
Exchange.
The Company has filed with the Commission a Registration Statement
(which term shall include all amendments, exhibits and schedules thereto) on
Form S-3 under the Securities Act of 1933 (the "Securities Act") with respect to
the Shares offered hereby. This Prospectus does not contain all the information
set forth in the Registration Statement, certain parts of which are omitted in
accordance with the rules and regulations of the Commission, and to which
reference is hereby made. Statements made in this Prospectus as to the contents
of any document referred to are not necessarily complete. With respect to each
such document filed as an exhibit to the Registration Statement, reference is
made to the exhibit for a more complete description of the matter involved, and
each such statement shall be deemed qualified in its entirety by such reference.
<PAGE>
RISK FACTORS
This Prospectus contains certain forward-looking statements within the
meaning of the Securities Act. Actual results could differ materially from those
projected in the forward-looking statements as a result of certain of the risk
factors set forth below and certain other factors set forth elsewhere in this
Prospectus. In addition to the other information contained and incorporated by
reference in this Prospectus, the following risk factors should be considered
carefully in evaluating the Company and its business before purchasing the
Shares offered hereby.
Dependence on Medicare, Medicaid and Other Sources of Reimbursement
The Company is reimbursed for dialysis services primarily at fixed
rates as established in advance under the Medicare End Stage Renal Disease
("ESRD") program. Under this program, once a patient becomes eligible for
Medicare reimbursement, Medicare is responsible for payment of approximately
80% of the composite rate for dialysis treatment. The composite rate is
determined by the Health Care Financing Administration ("HCFA") for
reimbursement of Medicare patients. Approximately 65% and 58% of the Company's
net patient revenue during the year ended December 31, 1995 and the nine months
ended September 30, 1996, respectively, was funded by Medicare. Since 1983,
numerous Congressional actions have resulted in changes in the Medicare
composite reimbursement rate from a national average of $138 per treatment in
1983 to a low of $125 per treatment on average in 1986 and to approximately
$126 per treatment on average at present. The Company is not able to predict
whether future rate changes will be made. Reductions in composite rates could
have a material adverse effect on the Company's revenues and net earnings.
Furthermore, increases in operating costs that are subject to inflation, such
as labor and supply costs, without a compensating increase in prescribed rates,
may adversely affect the Company's earnings in the future. The Company is also
unable to predict whether certain services, as to which the Company is
currently separately reimbursed, may in the future be included in the Medicare
composite rate.
Since June 1, 1989, the Medicare ESRD program has provided
reimbursement for the administration to dialysis patients of erythropoietin
("EPO"), a drug that is beneficial in the treatment of anemia, a complication
experienced by most dialysis patients. Most of the Company's dialysis patients
receive EPO. Revenues associated with the administration of EPO are significant
to the Company and the Company cannot predict future changes in the
reimbursement rate, the typical dosage per administration or the cost of EPO.
EPO is produced by only one manufacturer, and any interruption of supply could
adversely affect the Company's operations.
All of the states in which the Company currently operates dialysis
centers provide Medicaid (or comparable) benefits to qualified recipients to
supplement their Medicare entitlement. The Company estimates that approximately
4% of its net patient revenue during the fiscal year ended December 31, 1995 and
during the nine months ended September 30, 1996 was funded by Medicaid or
comparable state programs. The Medicaid programs are subject to statutory and
regulatory changes, administrative rulings, interpretations of policy and
governmental funding restrictions, all of which may have the effect of
decreasing program payments, increasing costs or modifying the way the Company
operates its dialysis business.
-2-
<PAGE>
Approximately 31% and 38% of the Company's net patient revenue during
the fiscal year ended December 31, 1995 and during the nine months ended
September 30, 1996, respectively, was from sources other than Medicare and
Medicaid. These sources include payments from third-party, non-government payers
and payments from hospitals with which the Company has agreements for the
provision of inpatient acute dialysis treatments, in each case at rates that
generally exceed the Medicare and Medicaid rates. Any restriction or reduction
of the Company's ability to charge for such services at rates in excess of those
paid by Medicare would adversely affect the Company's net patient revenue and
net income. The Company is unable to quantify or predict the degree, if any, of
the risk of reductions in payments under these various payment plans.
In October 1996, HCFA announced that four managed care companies had
been awarded contracts to develop and implement capitated reimbursement systems
for ESRD patients in their respective markets as part of a four-year
demonstration project. The demonstration project is intended to assist HCFA in
determining whether to allow open enrollment of ESRD patients into managed care
plans serving Medicare beneficiaries. Currently, managed care companies are
permitted to arrange for the provision of dialysis services only to existing
members in their programs who develop ESRD. The Company is unable to predict
whether the demonstration project will result in large numbers of ESRD patients
enrolling in managed care programs, or the impact of the enrollment of ESRD
patients in managed care programs on the Company. The widespread introduction of
managed care to dialysis services could result in a reduction in the rates of
reimbursement for the Company's services, which could have a material adverse
effect on the Company's revenues and net earnings.
Operations Subject to, and Potential Effects of, Governmental Regulation
The Company is subject to extensive regulation by both the Federal
government and the states in which it conducts its business, including the
illegal remuneration provisions of the Social Security Act and similar state
laws, which impose civil and criminal sanctions on persons who solicit, offer,
receive or pay any remuneration, directly or indirectly, in consideration for
referring a patient for treatment that is paid for in whole or in part by
Medicare, Medicaid or similar state programs. The Federal government has
published regulations that provide exceptions or safe harbors for certain
business transactions. Transactions that are structured within the safe harbors
are deemed not to violate the illegal remuneration provisions. Transactions that
do not satisfy all elements of a relevant safe harbor do not necessarily violate
the illegal remuneration statute, but may be subject to greater scrutiny by
enforcement agencies. The arrangements between the Company and the physician
directors of its dialysis centers ("Physician Directors") have been structured
to satisfy the elements of the applicable safe harbors, but there can be no
assurance that they will not be found to violate the illegal remuneration
provisions. In addition, certain of the Company's Physician Directors from whom
the Company has acquired dialysis centers have received shares of the Company's
Common Stock in full or partial consideration for such acquisitions, and other
Physician Directors may have purchased shares of the Company's Common Stock in
the open market. The Company believes that such security ownership falls within
one of the safe harbors, but there can be no assurance that such security
ownership will not be found to violate the illegal remuneration provisions.
Although the Company has never been challenged
-3-
<PAGE>
under these statutes and believes it complies in all material repsects with
these and all other applicable laws and regulations, there can be no assurance
that the Company will not be required to change its practices or relationships
with its Physician Directors or that the Company will not experience material
adverse effects as a result of any such challenge.
The Omnibus Budget Reconciliation Act of 1989 includes certain
provisions ("Stark I") that restrict physician referrals for clinical laboratory
services to entities with which a physician or an immediate family member has a
financial relationship. In August 1995, HCFA published regulations interpreting
Stark I. The regulations specifically provide that services furnished in an ESRD
facility that are included in the composite billing rate are excluded from the
coverage of Stark I. The Company believes that the language and legislative
history of Stark I indicate that Congress did not intend to include laboratory
services provided incidental to dialysis services within the Stark I
prohibition; however, laboratory services not included in the Medicare compos
ite rate could be included within the coverage of Stark I. Violations of Stark I
are punishable by civil penalties, which may include exclusion or suspension of
a provider from future participa tion in Medicare and Medicaid programs and
substantial fines. Due to the breadth of the statutory provisions and the
absence of regulations or court decisions addressing laboratory services not
included in the Medicare composite rate, it is possible that the Company's
practices might be challenged under this law.
The Omnibus Budget Reconciliation Act of 1993 includes certain
provisions ("Stark II") that restrict physician referrals for certain designated
health services to entities with which a physician or an immediate family member
has a financial relationship. The Company believes that the language and
legislative history of Stark II indicate that Congress did not intend to include
dialysis services and the services and items provided incident to dialysis
services within the Stark II prohibitions; however, certain services, including
the provision of, or arrangement and assumption of financial responsibility
for, outpatient prescription drugs, including EPO, and clinical laboratory
services, could be construed as designated health services within the meaning of
Stark II. Violations of Stark II are punishable by civil penalties, which may
include exclusion or suspension of the provider from future participation in
Medicare and Medicaid programs and substantial fines. Due to the breadth of the
statutory provisions and the absence of regulations or court decisions
addressing the specific arrangements by which the Company conducts its business,
it is possible that the Company's practices might be challenged under these
laws.
The Clinton administration's health care reform proposals, and other
health care reform proposals in general, have not addressed the Medicare ESRD
program. Nevertheless, health care reform in general, and Medicare reform in
particular, could bring radical change in the financing and regulation of the
health care business, and the Company is unable to predict the effect of such
changes on its future operations. Changes in reimbursement levels under Medicare
or Medicaid and changes in applicable governmental regulations could
significantly affect the Company's results of operations. It is uncertain at
this time what legislation on health care reform, if any, will ultimately be
implemented or whether other changes in the administration or interpretation of
governmental health care programs will occur. There can be no assurance that
future health care legislation or other changes in the administration or
interpretation of governmental health care programs will not have a material
adverse effect on the results of operations of the Company.
-4-
<PAGE>
Risks Inherent in Growth Strategy
The Company's business strategy depends in significant part on its
ability to acquire or develop additional dialysis centers. This strategy is
dependent on the continued availability of suitable acquisition candidates at
acceptable prices and subjects the Company to the risks inherent in assessing
the value, strengths and weaknesses of acquisition candidates, integrating and
managing the operations of acquired companies and identifying suitable locations
for additional facilities. The Company's growth is expected to place significant
demands on the Company's financial resources. The Company plans to borrow a
significant portion of the funds needed to acquire or develop centers in the
future. Although the Company's credit facility with a consortium of bank lenders
includes up to $100,000,000 for acquisition and development activities and
general working capital requirements, and the Company completed an offering of
$125,000,000 principal amount of 5 5/8% Convertible Subordinated Notes due 2006
on June 12, 1996, a portion of the proceeds of which will be used to fund future
acquisitions, additional equity or debt financings are expected to be required
in order for the Company to fund its expansion plans. There can be no assurance
that the Company will continue to be able to obtain necessary financing on
acceptable terms for the acquisition or development of centers or that the
Company will otherwise be successful in acquiring or developing new centers. No
assurance can be given that the Company will make any additional acquisitions or
develop any additional centers. See also "Risk Factors -Competition."
Dependence on Physician Referrals
The Company's centers are dependent upon referrals of ESRD patients
for treatment by physicians specializing in nephrology and practicing in the
communities served by the Company's dialysis centers. As is customary in the
dialysis industry, at each center one or a few physicians account for all or a
significant portion of the patient referral base. The loss of one or more key
referring physicians at a particular center could have a material adverse impact
on the operations of that center and could adversely affect the Company's
overall operations. Financial relationships with physicians and other
referral sources are highly regulated. The illegal remuneration provisions
of the Social Security Act and similar state laws prohibit contracts for
referrals.
Competition
The dialysis industry is fragmented and highly competitive,
particularly from the standpoint of competition for acquisition of existing
dialysis centers and developing relationships with referring physicians.
Competition for qualified physicians to act as Physician Directors is also
high. Also, a number of health care providers have entered or may decide to
enter the dialysis business. Certain of the Company's competitors have
substantially greater financial resources than the Company and may compete
with the Company for acquisitions and for development of centers in markets
targeted by the Company. There can be no assurance that the Company can
continue to compete effectively with such providers. In addition, competition
has increased the cost of acquiring existing dialysis facilities and there can
be no assurance that these costs will not continue to increase as a result of
future industry consolidation. Furthermore, some of the Company's centers are
in urban areas where there are many competing facilities in close proximity.
-5-
<PAGE>
The Company has also experienced competition from the establishment of
facilities by former Physician Directors and referring physicians.
Dependence on Key Personnel
The Company is dependent on certain key management personnel,
particularly its President and Chief Executive Officer, Robert L. Mayer, Jr.,
the loss of whom could have an adverse effect on the Company's business.
Moreover, the Company believes that its future success will be significantly
dependent on its ability to attract and retain qualified physicians to serve as
Physician Directors of its dialysis centers. In addition, the Company will need
to continue to attract and retain highly skilled nurses, competition for whom is
intense.
Volatility of Market Price of Common Stock
The trading price of the Common Stock is subject to significant
fluctuations in response to variations in quarterly operating results, general
conditions in the health care industry, changes in the regulatory environment
and other factors.
Shares Eligible for Future Sale
Of the 24,393,056 outstanding shares of Common Stock as of
December 12, 1996, 21,870,300 shares were freely tradeable and 2,522,756 shares
were restricted and therefore not freely tradeable. Of the restricted shares,
2,453,165 shares had been registered under the Securities Act on shelf
registration statements and were eligible for sale in the public market as of
December 12, 1996. The remaining 69,591 restricted shares are eligible for sale
in the public market pursuant to Rule 144 promulgated under the Securities Act,
and 1,598,199 shares subject to exercise of outstanding options as of
December 12, 1996 will become eligible for future sale in the public market as
they are exercised. Sales of a substantial number of shares of Common Stock in
the public market during or following the offering made hereby could adversely
affect prevailing market prices of the Common Stock.
Potential Anti-Takeover Effects of Delaware Law and By-law Provisions; Possible
Issuances of Preferred Stock
Certain provisions of Delaware law and the Company's By-Laws could
delay or impede the removal of incumbent directors and could make it more
difficult for a third party to acquire, or could discourage a third party from
attempting to acquire, control of the Company. Such provisions could limit the
price that certain investors might be willing to pay in the future for shares of
the Company's Common Stock. The Company's Board of Directors is divided into
three classes, with directors in each class elected for three-year terms. The
By-Laws impose various procedural and other requirements that could make it more
difficult for stockholders to effect certain corporate actions. Shares of
preferred stock may be issued by the Board of Directors without stockholder
approval on such terms and conditions, and having such rights, privileges and
preferences, as the Board may determine. The rights of the holders of Common
Stock will be subject to, and may be adversely affected by, the rights of the
holders of any preferred stock
-6-
<PAGE>
that may be issued in the future. The Company has no current plans to issue any
shares of preferred stock.
THE COMPANY
The Company is a leading, high-quality provider of dialysis treatments
and ancillary services to patients suffering from chronic kidney failure,
primarily in its freestanding outpatient dialysis treatment centers or in the
patient's home. The Company currently operates 114 outpatient dialysis centers
in 23 states and the District of Columbia and two dialysis centers in the
Republic of Argentina. As of January 20, 1997, the Company provided dialysis
services to approximately 8,300 patients. The Company also provided ancillary
medications and services to patients, the most significant of which is the
administration of EPO, a protein used to treat anemia, a complication
experienced by most dialysis patients. In addition, the Company provided
inpatient acute dialysis services to 92 hospitals located in its service areas
as of January 20, 1997. The Company has expanded rapidly, primarily through
acquisitions, increasing the number of dialysis centers in its network from 15
as of December 31, 1991 to its current level of 116 centers.
The Company is a Delaware corporation formed on August 11, 1988. Its
principal executive offices are located at 1180 West Swedesford Road, Building
2, Suite 300, Berwyn, Pennsylvania 19312, and its telephone number is
(610) 644-4796.
SELLING STOCKHOLDERS
The Shares covered by this Prospectus are, or may be, offered by the
Selling Stockholders. The Selling Stockholders are Richard W. Johns, Liliana
Barone and Miguel Curi.
The Selling Stockholders were granted options to purchase an aggregate
of 30,000 shares of the Company's Common Stock as partial consideration for
entering into a Purchase and Settlement Agreement dated December 16, 1996 (the
"Settlement Agreement") among the Selling Stockholders, RTC Holdings, Inc., a
subsidiary of the Company, and JBC S.A., an Argentine corporation affiliated
with the Selling Stockholders. The Settlement Agreement, among other things,
released RTC Holdings, Inc. from the obligation to issue shares of stock in RTC
Holdings S.A., a subsidiary of RTC Holdings, Inc., to JBC S.A. in consideration
of JBC S.A.'s assistance in increasing the number of patients at the Company's
dialysis centers in the Republic of Argentina.
Under the terms of the options, each Selling Stockholder has the right
to purchase 10,000 shares of the Company's Common Stock at a price of $23.50 per
share. Each option remains exercisable until the earlier of December 16, 2006 or
the expiration of one year from the date of the Selling Stockholder's death. The
options were fully exercisable on the date of grant, December 16, 1996, with the
exception of the option granted to Miguel Curi, which becomes exercisable upon
the earlier of (i) the date on which the number of patients at the Company's
dialysis centers in the Republic of Argentina exceeds 1,000 or (ii) January 1,
1998.
Except for Miguel Curi, none of the Selling Stockholders, nor any
affiliate of any of the Selling Stockholders, is now, or ever has been, an
officer, director or employee of the Company.
-7-
<PAGE>
Miguel Curi is employed by the Company as project manager for its Argentine
operations. In connection with the Settlement Agreement, the Selling
Stockholders also entered into a covenant not to compete with the Company that,
for a period of ten years, beginning in December 1996, restricts each of the
Selling Stockholders from soliciting clients, employees or contractors of the
Company's dialysis centers in the Republic of Argentina, from disclosing
information relating to the operations of the Company's dialysis centers in the
Republic of Argentina, and from any involvement in the provision of dialysis
services in the Republic of Argentina.
Pursuant to the Settlement Agreement, the Company granted the Selling
Stockholders certain registration rights with respect to the Shares purchasable
upon exercise of the options. The Company has agreed to register the shares on a
Form S-3 registration statement in a manner that will constitute a "shelf"
registration for purposes of Rule 415 under the Securities Act. The Registration
Statement is being filed by the Company in order to register the Shares and
fulfill the foregoing obligation of the Company.
Additional information as to the Selling Stockholders and their
beneficial ownership of the Company's Common Stock is set forth below. In
accordance with Rule 13d-3 under the Exchange Act, the Selling Stockholders are
deemed to beneficially own the Shares, because they have the right to acquire
the Shares within 60 days. Therefore, the Shares, although not yet purchased by
the Selling Stockholders, are included in the table below. Each Selling
Stockholder has sole investment and voting power with respect to the shares
listed below.
<TABLE>
<CAPTION>
Common Stock To
Be Beneficially
Common Stock Owned If All Shares
Beneficially Owned That May Be Offered
On January 1, 1997 Shares That Hereunder Are Sold
------------------ May Be Offered ------------------
Name Shares Percent Hereunder Shares Percent
- ----- ------ ------- -------------- ------ -------
<S> <C> <C> <C> <C> <C>
Richard W. Johns 10,000 * 10,000 --- ---
Liliana Barone 10,000 * 10,000 --- ---
Miguel Curi 10,000 * 10,000 --- ---
</TABLE>
- -----------
* Less than 1%.
Pledgees, donees or transferees of or other successors in interest to
the Selling Stockholders will be identified in a supplement to this Prospectus.
If the number of shares of Common Stock transferred is material, the new holders
of the shares transferred will also be identified in a post-effective amendment
to the Registration Statement.
-8-
<PAGE>
PLAN OF DISTRIBUTION
The Company has been advised that the distribution of the Shares by the
Selling Stockholders, or by pledgees, donees or transferees of or other
successors in interest to the Selling Stockholders, may be effected from time
to time in one or more transactions (which may involve block transactions) on
the New York Stock Exchange or such other exchange or market in which the Common
Stock may from time to time be trading, in negotiated transactions or in a
combination of any such transactions. Such transactions may be effected by the
Selling Stockholders at market prices prevailing at the time of sale, at prices
related to such prevailing market prices, at negotiated prices or at fixed
prices. The Selling Stockholders may effect such transactions by selling Shares
to or through broker-dealers, including purchases by a broker-dealer as
principal and resale by such broker-dealer for its account pursuant to this
Prospectus. Such broker-dealers will receive compensation in the form of
discounts or commissions from the Selling Stockholders and may receive
commissions from the purchasers of Shares for whom such broker-dealers may act
as agents (which discounts or commissions from the Selling Stockholders or such
purchasers, if in excess of those customary for the types of transactions
involved, will be disclosed in a supplemental prospectus).
Any broker-dealer that participates with the Selling Stockholders in the
distribution of Common Stock may be deemed to be an "underwriter" within the
meaning of the Securities Act of 1933, and any commissions or discounts received
by such broker-dealer and any profit on the resale of Shares by such broker-
dealer may be deemed to be underwriting discounts and commissions under the
Securities Act of 1933.
The respective costs and expenses of the registration of the Shares,
except for underwriting or selling discounts or commissions, will be paid by the
Company. These costs and expenses borne by the Company will include, without
limitation, all registration and filing fees, legal and accounting fees,
printing expenses and costs of special audits incident to or required by the
registration of the Shares.
USE OF PROCEEDS
The Company will not receive any of the proceeds from the resale of the
Shares offered hereunder by the Selling Stockholders.
INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
The following documents have been filed with the Commission and are
incorporated by reference in this Prospectus:
(a) The Company's Annual Report on Form 10-K for the fiscal year ended
December 31, 1995;
(b) The Company's Quarterly Report on Form 10-Q for the fiscal quarter
ended March 31, 1996, and Amendment No. 1 thereto on Form 10-Q/A filed June 6,
1996;
-9-
<PAGE>
(c) The Company's Quarterly Report on Form 10-Q for the fiscal quarter
ended June 30, 1996;
(d) The Company's Quarterly Report on Form 10-Q for the fiscal quarter
ended September 30, 1996;
(e) The Company's Current Report on Form 8-K dated February 20, 1996;
(f) The Company's Current Report on Form 8-K dated May 28, 1996;
(g) The Company's Current Report on Form 8-K dated May 29, 1996, and
Amendment No. 1 thereto on Form 8-K/A filed July 16, 1996;
(h) The Company's Current Report on Form 8-K dated August 23, 1996;
(i) The Company's Current Report on Form 8-K dated September 16, 1996;
(j) The Company's Current Report on Form 8-K dated September 16, 1996
and Amendment No. 1 thereto on Form 8-K/A filed November 27, 1996;
(k) The Company's Current Report on Form 8-K dated February 5, 1997;
and
(l) The description of the Company's Common Stock set forth in the
Company's Registration Statement No. 33-74994 on Form S-1, initially filed with
the Commission under the Securities Act on February 4, 1994, under the caption
"Description of Capital Stock -- Common Stock," which is incorporated by
reference in response to Item 1 of Registration Statement No. 1-14142 on Form 8-
A filed by the Company with the Commission on December 14, 1995 pursuant to
Section 12(b) of the Exchange Act.
All documents filed by the Company pursuant to Section 13(a), 13(c), 14
or 15(d) of the Exchange Act after the date of this Prospectus and prior to the
filing of a post-effective amendment which indicates that all securities
offered have been sold or which deregisters all securities then remaining
unsold, shall be deemed to be incorporated by reference in this Prospectus and
to be a part hereof from the date of filing of such documents. Any statement
incorporated herein shall be deemed to be modified or superseded for purposes of
this Prospectus to the extent that a statement contained herein or in any other
subsequently filed document which also is or is deemed to be incorporated by
reference herein modifies or supersedes such statement and any statement
contained herein shall be deemed to be modified or superseded for all purposes
to the extent that a statement contained in any subsequently filed document
which is deemed to be incorporated by reference modifies or supersedes such
statement.
The Company will provide without charge to each person to whom this
Prospectus is delivered, upon the request of such person, a copy of any or all
of the documents incorporated herein by reference, other than exhibits to such
documents (unless such exhibits are specifically incorporated by reference
herein). Such requests should be addressed to: Ronald H. Rodgers,
-10-
<PAGE>
Jr., Vice President of Finance, Renal Treatment Centers, Inc., 1180 West
Swedesford Road, Building 2, Suite 300, Berwyn, Pennsylvania 19312 (telephone:
610-644-4796).
LEGAL MATTERS
The validity of the issuance of the Shares offered hereby has been
passed upon for the Company by Duane, Morris & Heckscher, Philadelphia,
Pennsylvania. Thomas J. Karl, a partner of Duane, Morris & Heckscher, has served
as the Vice President, Secretary and General Counsel of the Company since May
27, 1996, and is the beneficial owner of 1,540 shares of the Company's Common
Stock. Mr. Karl also holds options to purchase 120,000 shares of Common Stock.
EXPERTS
The consolidated balance sheets, supplemental consolidated balance
sheets and restated consolidated balance sheets of the Company and its
subsidiaries as of December 31, 1995 and 1994 and the related consolidated
statements of income, stockholders' equity and cash flows, supplemental
consolidated statements of income, stockholders' equity and cash flows and
restated consolidated statements of income, stockholders' equity and cash flows
for each of the three years in the period ended December 31, 1995 incorporated
by reference in this Prospectus have been incorporated by reference herein in
reliance on the reports, which include references to information audited by
other auditors, of Coopers & Lybrand L.L.P., independent accountants, given on
the authority of that firm as experts in accounting and auditing, which reports
are also incorporated by reference herein.
The Company acquired Wichita Dialysis Group and Healthcare Corporation
and Affiliates in business combinations which have both been accounted for using
the pooling-of-interests method of accounting. The financial statements of
Wichita Dialysis Group and Healthcare Corporation and Affiliates as of December
31, 1993 and 1994 and for the years then ended were audited by Baird, Kurtz &
Dobson and Deloitte & Touche LLP, respectively, as stated in their reports
incorporated by reference herein, and have been so incorporated in reliance upon
the reports of such firms given upon their authority as experts in accounting
and auditing. Baird, Kurtz & Dobson and Deloitte & Touche LLP are independent
auditors. The reports of Coopers & Lybrand L.L.P., insofar as they relate to the
amounts included for Wichita Dialysis Group and Healthcare Corporation and
Affiliates, are based solely on the reports of Baird, Kurtz & Dobson and
Deloitte & Touche LLP, respectively.
The Company acquired KCDC/KCCC Group in a business combination that has
been accounted for using the purchase method of accounting. The combined balance
sheet of KCDC/KCCC Group as of December 31, 1995 and the related combined
statements of income, stockholders' equity and cash flows for the year then
ended incorporated by reference in this Prospectus have been incorporated by
reference herein in reliance on the report of Coopers & Lybrand L.L.P.,
independent accountants, given on the authority of that firm as experts in
accounting and auditing, which report is also incorporated by reference herein.
The Company acquired PCAKC/NFAKC Group in a business combination that
has been accounted for using the pooling-of-interests method of accounting. The
combined balance sheet
-11-
<PAGE>
of PCAKC/NFAKC Group as of December 31, 1995 and the related combined statements
of operations, stockholders' equity and cash flows for the year then ended
incorporated by reference in this Prospectus have been incorporated by reference
herein in reliance on the report of Coopers & Lybrand L.L.P., independent
accountants, given on the authority of that firm as experts in accounting and
auditing, which report is also incorporated by reference herein.
The Company acquired Columbus Regional Dialysis Center, Inc. ("CRDC")
and Phenix City Nephrology Referral Center, Inc. ("PCNRC") in a business
combination that has been accounted for using the purchase method of accounting.
The balance sheet of CRDC as of December 31, 1995 and the related statements of
retained earnings, income and cash flows for the year then ended and balance
sheet of PCNRC as of December 31, 1995 and the related statements of retained
earnings, income and cash flows for the year then ended incorporated by
reference in this Prospectus have been incorporated by reference herein in
reliance on the reports of Aronhalt, Stringer and Company, independent
accountants, given on the authority of that firm as experts in accounting and
auditing, which reports are also incorporated by reference herein.
-12-
<PAGE>
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
Item 14. Other Expenses of Issuance and Distribution.
<TABLE>
<S> <C>
Registration fee .................................................. $ 255
Legal fees and expenses ........................................... 5,000*
Accountants' fees and expenses .................................... 4,000*
Miscellaneous ..................................................... 500*
--------
Total.................................................... $ 9,755*
========
</TABLE>
- ----------------------------
*Estimated.
The Company will bear all of the foregoing expenses.
Item 15. Indemnification of Directors and Officers.
Section 145 of the General Corporation Law of the State of Delaware
empowers a Delaware corporation to indemnify any person who was or is a party or
is threatened to be made a party to any threatened, pending or completed action,
suit or proceeding, whether civil, criminal, administrative or investigative
(other than an action by or in the right of the corporation) by reason of the
fact that he is or was a director, officer, employee or agent of the
corporation, or is or was serving at the request of the corporation as a
director, officer, employee or agent of another corporation, partnership, joint
venture, trust or other enterprise, against expenses (including attorneys'
fees), judgments, fines and amounts paid in settlement actually and reasonably
incurred by him in connection with such action, suit or proceeding if he acted
in good faith and in a manner he reasonably believed to be in or not opposed to
the best interests of the corporation, and, with respect to any criminal action
or proceeding, had no reasonable cause to believe his conduct was unlawful. The
termination of any action, suit or proceeding by judgment, order, settlement,
conviction, or upon plea of nolo contendere or its equivalent, does not, of
itself, create a presumption that the person did not act in good faith and in a
manner which he reasonably believed to be in or not opposed to the best
interests of the corporation, and, with respect to any criminal action or
proceeding, had reasonable cause to believe that his conduct was unlawful.
In the case of an action or suit by or in the right of the corporation to
procure a judgment in its favor, Section 145 empowers a corporation to indemnify
any person who was or is a party or is threatened to be made a party to any
threatened, pending or completed action or suit by reason of the fact that he is
or was acting in any of the capacities set forth above against expenses
(including attorneys' fees) actually and reasonably incurred by him in
connection with the defense or settlement of such action or suit if he acted in
good faith and in a manner he reasonably believed to be in or not opposed to the
best interests of the corporation, except that indemnification is not permitted
in respect of any claim, issue or matter as to which such person is adjudged to
be liable to the corporation unless and only to the extent that the Court of
Chancery of the State
II-1
<PAGE>
of Delaware or the court in which such action or suit was brought determines
upon application that, despite the adjudication of liability but in view of all
the circumstances of the case, such person is fairly and reasonably entitled to
indemnity for such expenses which the Court of Chancery or such other court
deems proper.
Section 145 further provides: that a Delaware corporation is required to
indemnify a director, officer, employee or agent against expenses (including
attorneys' fees) actually and reasonably incurred by him in defense of any
action, suit or proceeding referred to above or in defense of any claim, issue
or matter therein to the extent that such person has been successful on the
merits or otherwise; that the indemnification provided for by Section 145 shall
not be deemed exclusive of any other rights to which the indemnified party may
be entitled; that the indemnification provided for by Section 145 shall, unless
otherwise provided when authorized or ratified, continue as to a person who has
ceased to be a director, officer, employee or agent and shall inure to the
benefit of such person's heirs, executors and administrators; and empowers the
corporation to purchase and maintain insurance on behalf of any person who is or
was a director, officer, employee or agent of the corporation against any
liability asserted against him and incurred by him in any such capacity or
arising out of his status as such, whether or not the corporation would have the
power to indemnify him against such liability under Section 145. A Delaware
corporation may provide indemnification only as authorized in the specific case
upon a determination that indemnification of the director, officer, employee or
agent is proper in the circumstances because he has met the applicable standard
of conduct. Such determination is to be made (i) by the board of directors by a
majority vote of a quorum consisting of directors who were not parties to such
action, suit or proceeding, or (ii) if such a quorum is not obtainable, or, even
if obtainable a quorum of disinterested directors so directs, by independent
legal counsel in a written opinion or (iii) by the stockholders.
Article Eighth of the Company's Restated Certificate of Incorporation
provides for indemnification of directors and officers of the Company to the
fullest extent permitted by the General Corporation Law of the State of
Delaware, as presently or hereafter in effect.
The Company provides liability insurance for each director and officer for
certain losses arising from claims or charges made against them while acting in
their capacities as directors or officers of the Company up to an aggregate of
$5,000,000 inclusive of defense costs, expenses and charges.
Additionally, Article Seventh of the Company's Restated Certificate of
Incorporation limits the liability of the Company's directors to the fullest
extent permitted by Section 102(b)(7) of the General Corporation Law of the
State of Delaware, as the same may be amended and supplemented. Section
102(b)(7) permits the certificate of incorporation of a Delaware corporation to
include a provision eliminating or limiting the personal liability of a director
of a corporation to the corporation or its stockholders for monetary damages for
breach of his fiduciary duty as a director; provided, however, that the
provision may not eliminate or limit the liability of a director for (i) any
breach of the director's duty of loyalty to the corporation or its stockholders;
(ii) acts or omissions not in good faith or which involve intentional misconduct
or a knowing violation of law; (iii) the unlawful payment of dividends or
unlawful purchase or redemption of
II-2
<PAGE>
stock under Section 174 of the General Corporation Law of the State of Delaware;
or (iv) any transaction from which the director derived an improper personal
benefit.
Item 16. Exhibits.
4.1 Specimen Certificate of Common Stock of the Company (incorporated here-
in by reference to Exhibit No. 4.1 filed under the Company's Annual
Report on Form 10-K for the year ended December 31, 1995).
4.2 Restated Certificate of Incorporation of the Company (incorporated
herein by reference to Exhibit No. 3.1 filed under the Company's
Quarterly Report on Form 10-Q for the quarter ended March 31, 1996).
4.2.1 Certificate of Amendment dated February 29, 1996 to Restated
Certificate of Incorporation of the Company (incorporated herein by
reference to Exhibit No. 3.1.1 filed under the Company's Quarterly
Report on Form 10-Q for the quarter ended March 31, 1996).
4.3 By-Laws of the Company and Amendment to By-Laws adopted February 9,
1993 (incorporated herein by reference to Exhibit No. 3.2 filed under
the Company's Form S-1 Registration Statement No. 33-59850).
5.1 Opinion of Duane, Morris & Heckscher.
23.1 Consent of Duane, Morris & Heckscher (included in their opinion filed
as Exhibit 5.1).
23.2 Consent of Coopers & Lybrand L.L.P.
23.3 Consent of Deloitte & Touche LLP.
23.4 Consent of Baird, Kurtz & Dobson.
23.5 Consent of Aronhalt, Stringer and Company, CPA's.
24.1 Power of Attorney (see page II-6).
Item 17. Undertakings.
The undersigned registrant hereby undertakes:
(a) to file, during any period in which offers or sales are being made, a
post-effective amendment to this Registration Statement:
(i) to include any prospectus required by Section 10(a)(3) of the
Securities Act;
II-3
<PAGE>
(ii) to reflect in the prospectus any facts or events arising after
the effective date of this Registration Statement (or the most recent post-
effective amendment hereto) which individually or in the aggregate, represent a
fundamental change in the information set forth in this Registration Statement;
and
(iii) to include any material information with respect to the plan
of distribution not previously disclosed in this Registration Statement or any
material change to such information in this Registration Statement;
provided, however, that the undertakings set forth in paragraphs (i) and (ii)
above shall not apply if the information required to be included in a post-
effective amendment by those paragraphs is contained in periodic reports filed
by the registrant pursuant to Section 13 or 15(d) of the Exchange Act that are
incorporated by reference in this Registration Statement;
(b) that, for the purpose of determining any liability under the
Securities Act of 1933, each such post-effective amendment shall be deemed to be
a new registration statement relating to the securities offered therein, and the
offering of such securities at that time shall be deemed to be the initial bona
fide offering thereof; and
(c) to remove from registration by means of a post-effective amendment any
of the securities being registered which remain unsold at the termination of the
offering.
The undersigned registrant hereby further undertakes that, for purposes of
determining any liability under the Securities Act of 1933, each filing of the
registrant's annual report pursuant to Section 13(a) or Section 15(d) of the
Exchange Act (and, where applicable, each filing of an employee benefit plan's
annual report pursuant to Section 15(d) of the Exchange Act) that is
incorporated by reference in the Registration Statement shall be deemed to be a
new registration statement relating to the securities offered therein, and the
offering of such securities at that time shall be deemed to be the initial bona
fide offering thereof.
Insofar as indemnification for liabilities arising under the Securities
Act of 1933 may be permitted to directors, officers and controlling persons of
the registrant, the registrant has been advised that in the opinion of the
Securities and Exchange Commission such indemnification is against public policy
as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In
the event that a claim for indemnification against such liabilities (other than
the payment by the registrant of expenses incurred or paid by a director,
officer or controlling person of the registrant in the successful defense of any
action, suit or proceeding) is asserted by such director, officer or controlling
person in connection with the securities being registered, the registrant will,
unless in the opinion of its counsel the matter has been settled by controlling
precedent, submit to a court of appropriate jurisdiction the question whether
such indemnification by it is against public policy as expressed in the
Securities Act of 1933 and will be governed by the final adjudication of such
issue.
II-4
<PAGE>
The undersigned registrant hereby undertakes that:
(1) For purposes of determining any liability under the Securities Act of
1933, the information omitted from the form of prospectus filed as part of this
registration statement in reliance upon Rule 430A and contained in a form of
prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h)
under the Securities Act of 1933 shall be deemed to be part of this registration
statement as of the time it was declared effective.
(2) For the purpose of determining any liability under the Securities Act
of 1933, each post-effective amendment that contains a form of prospectus shall
be deemed to be a new registration statement relating to the securities offered
therein, and the offering of such securities at that time shall be deemed to be
the initial bona fide offering thereof.
II-5
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant
certifies that it has reasonable grounds to believe that it meets all of the
requirements for filing on Form S-3 and has duly caused this Registration
Statement to be signed on its behalf by the undersigned, thereunto duly
authorized, in Berwyn, Pennsylvania on February 6, 1997.
RENAL TREATMENT CENTERS, INC.
By: /s/ Robert L. Mayer, Jr.
------------------------------
Robert L. Mayer, Jr.,
President
Know all men by these presents, that each person whose signature appears
below constitutes and appoints Thomas J. Karl and Ronald H. Rodgers, Jr., and
each or both of them, as his true and lawful attorneys-in-fact and agents, with
full power of substitution, for him, and in his name, place and stead, in any
and all capacities to sign any or all amendments or post-effective amendments to
this Registration Statement, as well as any related registration statement, or
amendment thereto, filed pursuant to Rule 462 promulgated under the Securities
Act of 1933, and to file the same, with all exhibits thereto and other documents
in connection therewith, with the Securities and Exchange Commission, granting
unto said attorneys-in-fact and agents full power and authority to do and
perform each and every act and thing requisite and necessary to be done in and
about the premises, as fully to all intents and purposes as he might or could do
in person, hereby ratifying and confirming all that said attorneys-in-fact and
agents, or any of them or their substitutes, may lawfully do or cause to be done
by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this
Registration Statement has been signed below by the following persons in the
capacities and on the dates indicated.
<TABLE>
<CAPTION>
Signature Title Date
--------- ----- ----
<S> <C> <C>
/s/ Robert L. Mayer, Jr. President and Director February 6, 1997
- --------------------------- (principal executive officer)
Robert L. Mayer, Jr.
/s/ Frederick C. Jansen Executive Vice President, Chief February 6, 1997
- --------------------------- Financial Officer and Director
Frederick C. Jansen (principal financial officer)
/s/ Ronald H. Rodgers, Jr. Vice President of Finance February 6, 1997
- --------------------------- (principal accounting officer)
Ronald H. Rodgers, Jr.
/s/ Claire W. Gargalli Director January 27, 1997
- ---------------------------
Claire W. Gargalli
/s/ Patrick T. Ryan Director February 6, 1997
- ---------------------------
Patrick T. Ryan
/s/ Michael R. Walker Director February 6, 1997
- ---------------------------
Michael R. Walker
</TABLE>
II-6
<PAGE>
EXHIBIT INDEX
(Pursuant to Item 601 of Regulation S-K)
<TABLE>
<CAPTION>
Exhibit No. Exhibit
<S> <C>
4.1 Specimen Certificate of Common Stock of the Company
(incorporated herein by reference to Exhibit No. 4.1 filed
under the Company's Annual Report on Form 10-K for the year
ended December 31, 1995).
4.2 Restated Certificate of Incorporation of the Company
(incorporated herein by reference to Exhibit No. 3.1 filed
under the Company's Quarterly Report on Form 10-Q for the
quarter ended March 31, 1996).
4.2.1 Certificate of Amendment dated February 29, 1996 to Restated
Certificate of Incorporation of the Company (incorporated
herein by reference to Exhibit No. 3.1.1 filed under the
Company's Quarterly Report on Form 10-Q for the quarter ended
March 31, 1996).
4.3 By-Laws of the Company and Amendment to By-Laws adopted
February 9, 1993 (incorporated herein by reference to Exhibit
No. 3.2 filed under the Company's Form S-1 Registration
Statement No. 33-59850).
5.1 Opinion of Duane, Morris & Heckscher.
23.1 Consent of Duane, Morris & Heckscher (included in their opinion
filed as Exhibit 5.1).
23.2 Consent of Coopers & Lybrand L.L.P.
23.3 Consent of Deloitte & Touche LLP.
23.4 Consent of Baird, Kurtz & Dobson.
23.5 Consent of Aronhalt, Stringer and Company, CPA's.
24.1 Power of Attorney (see page II-6).
</TABLE>
<PAGE>
[LETTERHEAD OF DUANE, MORRIS, & HECKSCHER APPEARS HERE]
EXHIBIT 5.1
- -----------
February 6, 1997
The Board of Directors of
Renal Treatment Centers, Inc.
1180 W. Swedesford Road
Building 2, Suite 300
Berwyn, Pennsylvania 19312
Gentlemen:
We have acted as counsel to Renal Treatment Centers, Inc. (the "Company")
in connection with the preparation and filing with the Securities and Exchange
Commission under the Securities Act of 1933, as amended, of a Registration
Statement on Form S-3 (the "Registration Statement") relating to the offer and
sale by certain stockholders of the Company of up to an aggregate of 30,000
shares (the "Shares") of common stock, $.01 par value, of the Company issuable
upon the exercise of certain stock options (the "Options").
As counsel to the Company, we are familiar with all corporate proceedings
in connection with the preparation and filing of the Registration Statement. We
have also examined the Company's Restated Certificate of Incorporation and By-
Laws, each as amended to date, the corporate minutes and other proceedings and
records relating to the authorization and granting of the Options and the
authorization, sale and issuance of the Shares upon exercise of the Options, and
such other documents and matters of law as we have deemed necessary or
appropriate in order to render this opinion. Based upon the foregoing, it is our
opinion that the Shares, when issued in accordance with the terms and conditions
of the Options, will be duly authorized, legally and validly issued and
outstanding, fully paid and nonassessable.
We hereby consent to the use of this opinion in the Registration
Statement, and we further consent to the reference to our name in the Prospectus
under the caption "Legal Matters."
Sincerely,
/s/ Duane, Morris & Heckscher
<PAGE>
EXHIBIT 23.2
- ------------
CONSENT OF INDEPENDENT ACCOUNTANTS
We consent to the incorporation by reference in this registration statement of
Renal Treatment Centers, Inc. (the "Company") on Form S-3 of our reports dated
(i) March 20, 1996, which includes reference to information audited by other
auditors for which the dates of their reports are July 14, 1995 and March 31,
1995, respectively, on our audits of the consolidated financial statements and
financial statement schedule of the Company as of December 31, 1994 and 1995,
and for each of the three years in the period ended December 31, 1995, (ii)
March 20, 1996, except for the combination described in Note 2, for which the
date is August 19, 1996, which includes reference to information audited by
other auditors for which the dates of their reports are July 14, 1995 and March
31, 1995, respectively, on our audits of the supplemental consolidated financial
statements and financial statement schedule of the Company as of December 31,
1994 and 1995, and for each of the three years in the period ended December 31,
1995, which have been prepared to give retroactive effect to the merger of the
Company and Panama City Artificial Kidney Center, Inc. and North Florida
Artificial Kidney Center, Inc. (PCAKC/NFAKC Group) on July 23, 1996, which has
been accounted for as a pooling-of-interests, as described in Note 2 to the
consolidated financial statements, (iii) March 20, 1996, except for the
combination described in Note 2, for which the date is August 19, 1996, which
includes reference to information audited by other auditors for which the dates
of their reports are July 14, 1995 and March 31, 1995, respectively, on our
audits of the consolidated financial statements and financial statement schedule
of the Company as of December 31, 1994 and 1995, and for each of the three years
in the period ended December 31, 1995, which have been prepared to give
retroactive effect to the merger of the Company and PCAKC/NFAKC Group on July
23, 1996, which has been accounted for as a pooling-of-interests, as described
in Note 2 to the consolidated financial statements, (iv) June 26, 1996 on our
audit of the combined statements of the KCDC/KCCC Group as of December 31, 1995
and for the year then ended, and (v) August 7, 1996 on our audit of the combined
financial statements of PCAKC/NFAKC Group as of December 31, 1995 and for the
year then ended, which reports are incorporated herein by reference.
We also consent to the reference in this registration statement of Form S-3 to
our Firm under the caption "Experts."
Coopers & Lybrand L.L.P.
600 Lee Road
Wayne, Pennsylvania
February 6, 1997
<PAGE>
EXHIBIT 23.3
- ------------
INDEPENDENT AUDITORS' CONSENT
We consent to the incorporation by reference in this Registration Statement of
Renal Treatment Centers, Inc. on Form S-3 of our report date March 31, 1995,
appearing in the Annual Report on Form 10-K of Renal Treatment Centers, Inc. for
the year ended December 31, 1995 and to the reference to us under the heading
"Experts" in the Prospectus, which is part of this Registration Statement.
/s/ Deloitte & Touche LLP
DELOITTE & TOUCHE LLP
Nashville, Tennessee
February 4, 1997
<PAGE>
EXHIBIT 23.4
- ------------
CONSENT OF INDEPENDENT ACCOUNTANTS
We consent to the incorporation by reference in this Registration Statement of
Renal Treatment Centers, Inc. on Form S-3 of our report dated July 14, 1995,
except for Note 9 as to which the date is July 24, 1995, relating to the
financial statements of the Wichita Dialysis Group, appearing in the Form 10-K
Annual Report of Renal Treatment Centers, Inc. for the fiscal year ended
December 31, 1995 and to the reference to us under the heading "Experts" in the
Prospectus, which is part of this Registration Statement.
/s/ Baird, Kurtz & Dobson
BAIRD, KURTZ & DOBSON
Wichita, Kansas
February 4, 1997
<PAGE>
EXHIBIT 23.5
- ------------
INDEPENDENT AUDITORS' CONSENT
We consent to the incorporation by reference in this Registration Statement of
Renal Treatment Centers, Inc. on Form S-3 of our reports dated October 31, 1996,
appearing in the Current Report on Form 8-K/A Amendment No. 1 of Renal Treatment
Centers, Inc. dated September 16, 1996 and to the reference to us under the
heading "Experts" in the Prospectus, which is part of this Registration
Statement.
/s/ Aronhalt, Stringer and Company, CPA's
ARONHALT, STRINGER AND COMPANY, CPA'S
Upper Marlboro, Maryland
February 4, 1997
